论文部分内容阅读
肿瘤坏死因子相关凋亡配体(TRAIL),属于肿瘤坏死因子超家族成员,因其能特异性结合受体诱导肿瘤细胞凋亡,且对正常细胞没有明显损伤,使其成为一种极具发展潜能的抗肿瘤治疗药物。文献报道称以TRAIL为基础的多药联合治疗具有协同作用,可增强TRAIL受体靶向治疗的疗效。文章就以TRAIL为基础多药联合治疗的信号通路及协同作用机制作一综述。
Tumor necrosis factor-related apoptosis (TRAIL), a member of the tumor necrosis factor superfamily, is a highly developed member of the family because it specifically binds to the receptor and induces apoptosis in tumor cells without significant damage to normal cells Potential anti-cancer drugs. Reported in the literature that TRAIL-based multi-drug combination has a synergistic effect, can enhance the efficacy of TRAIL receptor targeted therapy. This review summarizes the signaling pathways and synergistic mechanisms of TRAIL-based multidrug combination therapy.